NEW YORK – TruDiagnostic said Wednesday that it is partnering with Finnish startup Nadmed to launch that firm's blood-based nicotinamide adenine dinucleotide (NAD) test in the US.
The CE-marked Q-Nadmed kit is used to analyze oxidized and reduced NAD metabolites, NAD+ and NADH, levels of which decline with age. Abnormal levels of those metabolites have been associated with improper immune function, metabolic disease, dementia, neurodegeneration, and heart disease, among other conditions, the companies said.
Financial and other terms of the deal were not disclosed.
Q-Nadmed is a laboratory-based test that uses enzymatic reactions and colorimetric detection to identify metabolite quantities. The firms said the test provides quick, reliable, quantitative detection.